Related Experiment Video
Updated: May 16, 2026
Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Value of Blood Count-Derived Inflammatory Markers for Evaluating Psoriasis Severity: Pilot Cross-Sectional
Luyuan Wang1,2, Xiaorui Zhang1,2, Chuangang Xia1
1Department of Dermatology and Venereology, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China.
Background:
Objective indicators are urgently needed to evaluate and monitor disease progression in patients with psoriasis.
Objective:
This study aimed to verify the correlations between blood count-derived inflammatory markers and the Psoriasis Area and Severity Index (PASI) among patients with psoriasis and explore the value of applying the PASI in combination with proinflammatory factors.
Methods:
This was a cross-sectional observational study that enrolled 719 patients from 2 tertiary hospitals. Receiver operating characteristic curve analysis and binary logistic regression models were applied to assess the evaluative power of blood count-derived inflammatory markers and their consistency with the PASI for stratifying psoriasis severity. The association with the PASI and the combination with proinflammatory factors of the blood count-derived inflammatory markers in 60 patients were analyzed. The exploratory association between blood count-derived markers and proinflammatory factors was analyzed using product terms. To ensure robustness, multivariable combined models were evaluated using receiver operating characteristic curves and decision curve analysis. Model performance was further validated via calibration plots and a predictive nomogram, with the decision curve analysis net benefit axis increased to 1.0 for comprehensive visualization.
Results:
The area under the curve showed that the systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI) were effective in reflecting psoriasis severity and showed advantages in patients with psoriasis complicated by arthritis and cardiovascular metabolic diseases. The comprehensive test showed quite appropriate consistency of the SIRI and PASI in distinguishing severity. The SII, SIRI, and AISI were significantly correlated with interleukin (IL)-6 in lesions (all P<.05), and the combinations of these indices with IL-6, IL-1, and IL-17 were also significantly correlated with the PASI (all P<.05).
Conclusions:
Blood count-derived inflammatory markers could better reflect the inflammation of patients with psoriasis. The SII, SIRI, and AISI have important clinical significance in evaluating disease severity. The combination with proinflammatory factors showed an advantage.
